Abstract
•There is a critical need for therapeutic options in uterine serous carcinoma (USC).•A substantial proportion of USC cases express estrogen receptors (ER).•This report describes use of letrozole therapy in recurrent, ER-positive USC.•Zoledronic acid may enhance letrozole efficacy against hormone-sensitive tumors.•Aromatase inhibitors could be a potential treatment option in ER-positive USC.